羟基喜树碱化疗栓塞联合手术切除治疗肝癌的疗效分析  

Effect of hydroxycamptothecin-based transcather arterial chemoembolization combined with hepatectomy for liver cancer

作　　者：宋宇豹[1] 高泽峰[1] 闫志峰[1] 赵玉山[2] Song Yubao;Gao Zefeng;Yan Zhifeng;Zhao Yushan(Department of General Surgery of Shanxi Provincial Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院普外二科,太原030013 [2]山西省肿瘤医院介入科,太原030013

出　　处：《中华普通外科杂志》2019年第2期118-121,共4页Chinese Journal of General Surgery

摘　　要：目的分析羟基喜树碱化疗栓塞术前辅助治疗对原发性肝癌患者手术切除的影响。方法选取山西省肿瘤医院普外二科收治的原发性肝癌患者64例,按照随机数字表法分为对照组和研究组,每组32例。对照组采用单纯手术方式治疗,研究组采用手术联合术前辅助羟基喜树碱化疗栓塞治疗。比较两组患者ALT、AST、ALB、TBiL及术后0.5年、1年、2年的复发率和生存率。结果研究组患者治疗后0.5年和1年复发率分别为9.38%和28.13%,与对照组相比差异有统计学意义;两组患者2年的复发率差异无统计学意义。研究组患者治疗后0.5年、1年及2年的生存率分别为93.75%、84.38%和65.63%,显著优于对照组。研究组患者治疗后AST(86±42)U/L和ALT(96±55)U/L,水平低于对照组,ALB(32±10)g/L和TBiL(24±9)μmol/L与对照组患者比较差异无统计学意义。结论原发性肝癌患者术前行预防性羟基喜树碱化疗栓塞治疗效果优于单纯手术切除治疗。Objective To evaluate transcather arterial chemoembolization (TACE) with hydroxycamptothecin combined with hepatectomy in treatment of primary liver cancer. Methods 64 primary liver cancer cases admitted and treated in Shanxi Provincial Cancer Hospital were divided into two groups with 32 cases in each.The control group were treated by surgery only and in the study group patients received TACE and hepatectomy. Results 0.5-year and 1-year recurrence rate in the study group were respectively 9.38% and 28.13%,significantly lower than those in the control group.There was no significant difference in the 2-year recurrence rate between the two groups.0.5-year,1-year and 2-year survival rate in the study group were respectively 93.75%,84.38% and 65.63%,significantly better than those in the control group.The AST and ALT were respectively (86±42)U/L,(96±55)U/L which were lower than those in the control group.The ALB and TBiL were respectively (32±10)g/L and (24±9)μmol/L,which were not significantly different with the control group. Conclusion Hydroxycamptothecin-based TACE combined with hepatectomy is better than hepatectomy only for the treatment of primary liver cancer.

关 键 词：癌 肝细胞 抗肿瘤联合化疗方案 喜树碱 

分 类 号：R735.7[医药卫生—肿瘤]